Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of December 2018, with the report dated December 13, 2018. The filing serves to update shareholders on a previously announced binding letter of intent dated October 22, 2018, between the Company and FSD Pharma Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate transaction update and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is the issuance of a press release (Exhibit 99.1) providing an update on the proposed transaction with FSD Pharma Inc. No financial changes versus a prior comparable period are reported in this document.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the proposed FSD Pharma Inc. transaction. Management notes that actual results could differ materially from expectations due to various risks and uncertainties. These risks are detailed in the "Risk Factors" section of the Company's Annual Report on Form 20-F filed on April 30, 2018, and subsequent filings. The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific details on the FSD Pharma Inc. transaction update.
- Review the "Risk Factors" in the Form 20-F filed on April 30, 2018, to understand the uncertainties surrounding the proposed transaction.
- Confirm the current status of the binding letter of intent dated October 22, 2018, as this filing only references an update rather than a completed agreement.